{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011629","form_type":"8-K","ticker":"FEED","cik":"0001326706","company_name":"ENvue Medical, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.784354+00:00","generated_at":"2026-06-04T05:50:52.262890+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield","bullets":["Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.","Fee payable monthly, due 45 days after invoice; late fee 1.5% per month; Veranex may suspend services if payment not made.","Either party may terminate on 60 days' notice; Veranex can also terminate for repeated late payments or relationship issues.","CEO Brian Murphy stated partnership aims to add therapeutic functionality and reduce cost of goods; press release dated March 28, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011629","json":"https://secwatch.observer/filing/0001493152-24-011629.json","markdown":"https://secwatch.observer/filing/0001493152-24-011629.md","text":"https://secwatch.observer/filing/0001493152-24-011629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:50:52.262890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41b66d0be92706d25d2a73f321aed7337feb8e7c","claim":"ENvue Medical, Inc. entered into Agreement with Veranex, Inc. valued at approximately $1.1 million (effective 2024-03-22).","evidence_excerpt":"On March 22, 2024, NanoVibronix, Inc., a New York corporation, (the “Company”), entered into a standalone services agreement (the “Agreement”), by and between the Company and Veranex, Inc., a Delaware corporation","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Veranex, Inc."},{"label":"Value","value":"approximately $1.1 million"},{"label":"Effective","value":"2024-03-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}